Hipermex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hipermex

Quick Facts

Property Description
Active ingredient Meclozine (Meclizine)
Form Oral tablets, Chewable tablets
Pharmacological class H₁ Receptor Antagonist, Antiemetic, Antivertigo Agent
General purpose Alleviating vertigo, motion sickness, nausea, and vomiting
Origin Synthetic (Piperazine derivative)

What Type of Medicine is Hipermex (Meclozine)?

Hipermex is a medicinal product containing the active ingredient Meclozine, which is also recognized internationally as meclizine. This agent is chemically a synthetic piperazine derivative and is classified pharmacologically as a first-generation antihistamine. Its primary application, however, is not for allergies, but as a specialized antivertigo agent and an antiemetic. It is structured as a single-ingredient product, typically available for oral administration in the form of tablets.

The chemical structure and pharmacological profile of Meclozine allow for a targeted effect focused on balance and motion, a key differentiating factor from antihistamines used for general allergy relief. Meclozine is recognized for its role in stabilizing balance. Hipermex, as a formulation of Meclozine, is utilized for managing anticipated motion disturbances, such as those encountered during sea travel.


How Does Hipermex Relate to Motion Sickness and Vertigo?

The general purpose of Hipermex is to provide relief by stabilizing the central nervous system's response to overstimulation arising from excessive motion or inner ear issues. Meclozine’s action relies on two properties: H₁ receptor antagonism and distinct anticholinergic properties. This dual mechanism is recognized for its ability to depress the excitability of relevant nerve pathways.

The compound specifically reduces the over-activity of the vestibular apparatus in the inner ear, which governs the body's balance, while also suppressing signals originating from the brain's chemoreceptor trigger zone (CTZ). This focused, central effect directly addresses symptoms. For instance, when a patient experiences vertigo (spinning) or anticipatory nausea, this mechanism helps to mitigate those involuntary reflexes, affirming the medicine’s general therapeutic utility.

What side effects are possible with Hipermex?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Hipermex (Meclozine) as listed in government regulatory summaries.


Adverse Reaction Classifications

The most frequently reported adverse reactions are related to its actions on the Nervous System and are often classified as Common. These include drowsiness, headache, and fatigue. Effects on the Gastrointestinal system are also common, such as dry mouth and occasional vomiting.

System-Organ Class Common Adverse Reactions
Nervous System Drowsiness, Fatigue, Headache
Gastrointestinal Dry mouth, Vomiting
Eye Disorders Blurred vision (Rare)

Serious adverse reactions are rare but officially documented, including the potential for an Anaphylactic reaction (severe, acute hypersensitivity).


Regulatory Safety Considerations

The official labeling notes specific constraints primarily related to the drug's anticholinergic properties. Caution is advised for use in older adults, who may experience an increased risk of sedation and urinary retention, and in individuals with pre-existing conditions like angle-closure glaucoma or prostatic enlargement.

Furthermore, the medication is contraindicated in individuals with known hypersensitivity to the drug. Regulatory documents also specify that simultaneous use with other Central Nervous System (CNS) depressants, including alcohol, may result in additive depressant effects. Safety and effectiveness have not been established in children under 12 years of age.

Overdose and Emergency Response

Official Regulatory Information on Overdose

The official overdose profile for Hipermex (Meclizine) is defined by a range of documented central nervous system (CNS) effects and anticholinergic manifestations. Documented CNS effects include signs of depression, such as extreme drowsiness, confusion, and sedation, potentially escalating to coma. Conversely, signs of CNS stimulation, including hallucinations and seizures, are also listed. Anticholinergic manifestations include clinical findings such as dilated pupils, dry mouth, flushing, fever, and a rapid heartbeat. Severe outcomes documented in regulatory sources include seizures, irregular heart rhythm, and depressed breathing.

Population Specific Overdose Manifestation
Children CNS stimulation and anticholinergic effects are noted as more likely to occur.
Elderly Hypotension (low blood pressure) may occur during overdose.

Overdose requires immediate medical attention. When severe signs are present, such as collapse, seizure, trouble breathing, or inability to be awakened, emergency services must be called immediately. Management is focused on symptomatic and supportive treatment in a hospital setting, as no specific antidote is known for Meclizine. Absorption reduction measures, such as activated charcoal or gastric lavage, are described procedures if ingestion was recent.

Therapeutic Uses of Hipermex

What Hipermex Treats: Main Uses and Benefits

Hipermex is considered relevant in clinical settings that involve acute or unstable symptom patterns linked to the body's balance and motion perception. It is applicable across domains where additional symptomatic support is needed to address groups of symptoms that may become intense or disruptive. The medication is used for managing the symptoms of motion sickness and easing manifestations of vertigo associated with vestibular system diseases.

Mitigating Severe Dizziness and Balance Issues (Vertigo)

Hipermex is commonly used across conditions presenting with acute episodes of vertigo—the intense sensation of spinning or unsteadiness—that are associated with diseases affecting the vestibular system (e.g., inner ear issues). In situations where patients experience heightened discomfort, this medication provides support that helps ease the overall symptom burden and may assist with maintaining a sense of stability when symptoms are more noticeable. It is applied across domains where additional symptomatic support is needed.

Preventing and Alleviating Motion Sickness Symptoms

It is also commonly used to help address symptom clusters related to physical discomfort during movement, specifically the nausea, vomiting, and dizziness associated with motion sickness (kinetosis). Applied in scenarios where additional management of discomfort is required, such as sea or air travel, it contributes to improved comfort during periods of heightened symptoms. This helps patients cope more steadily with symptom fluctuations.

“This medication is considered relevant for easing challenging symptomatic manifestations, particularly those linked to inner ear dysfunction and movement.”

Quick Fact: Relief for Vertigo and Motion Sickness
Primary Indication Areas: Balance Disorders and Kinetosis
Core Symptoms Addressed: Spinning Sensation, Disequilibrium, Nausea, and Vomiting
Patient Benefit: Supports comfort and stability during acute symptomatic episodes
Typical Context: Travel (prophylactic use) and Inner Ear Flares

Regulatory References

  1. DailyMed official labeling for Meclizine Hydrochloride

Eligibility and Restrictions for Use

Official Eligibility for Hipermex (Meclizine)

The use of Hipermex is defined by specific population eligibility rules established in official regulatory documents.

Who Must Not Use the Medicine (Contraindication) The medicine is strictly contraindicated in any individual with a known history of hypersensitivity or allergic reaction to meclizine or any other component listed in the formulation.

Age-Based Use

  • Adults (18+): Use is generally allowed for both vertigo and motion sickness.
  • Children (12 years and older): Use is permitted for motion sickness.
  • Children (Under 12 years): Use is not recommended because safety and effectiveness in this specific age group have not been formally established by regulatory bodies.
  • Older Adults: Dose selection must be cautious, typically starting at the lower end of the dosing range, reflecting the greater frequency of reduced organ function.

Conditional Use and Cautionary Status The medicine must be administered with caution in specific patient groups:

  • Comorbidities: Caution is required for patients with asthma, glaucoma, or enlargement of the prostate gland due to the drug's anticholinergic properties.
  • Organ Function: Caution should be exercised for patients with hepatic impairment (liver dysfunction) or renal impairment (kidney dysfunction) due to the potential for the medicine or its metabolites to accumulate.
  • Pregnancy/Lactation: Use during pregnancy is allowed only if clearly necessary; caution is advised during breastfeeding as it is unknown if meclizine is excreted into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Category Official Regulatory Documentation Statement
Medicinal product categories with documented interactions: CNS depressants (including sedatives and tranquilizers)
Specific interacting medicines (if explicitly listed): Monoaminooxidase (MAO) inhibitors (listed for potentiating anticholinergic effects)
Mechanistic basis of interactions (only if stated in label): Pharmacokinetic interaction: Meclizine is metabolized by CYP2D6 (based on in-vitro evaluation).
Pharmacodynamic interaction: Co-administration may result in increased CNS depression (additive sedative effect).
Timing-based interaction rules (if applicable): None explicitly stated (No mandatory administration timing or separation windows are specified in official labels).
Population-specific interaction notes (if applicable): Hepatic Impairment may result in increased systemic exposure of the drug.
Renal Impairment may result in a potential for drug/metabolite accumulation.

Official Interaction Statements and Restrictions

Official interaction statements:

  • Co-administration with other CNS depressants may result in increased CNS depression.
  • There is a possibility for a drug interaction with CYP2D6 inhibitors because meclizine is metabolized by the CYP2D6 enzyme.
  • Monoaminooxidase (MAO) inhibitors may prolong and intensify the anticholinergic effects of meclizine.
  • Caution is advised in patients with hepatic impairment and renal impairment due to the potential for increased systemic exposure or drug/metabolite accumulation.

Interaction-related restrictions:

  • Patients are cautioned to avoid alcoholic beverages while taking the medication.

Connection to the overall interaction profile:

Regulatory documents define the product's interaction structure based on both metabolic processing and pharmacodynamic class. The profile establishes additive CNS effects as the primary pharmacodynamic risk with other depressants and alcohol. Furthermore, the structure identifies CYP2D6 inhibition as the central pharmacokinetic concern for altered systemic exposure, while explicitly addressing accumulation risk in patients with hepatic or renal impairment.

Mechanism of Action

Hipermex (meclizine) functions primarily as a non-selective antagonist at the central histamine H1 receptors. The drug readily crosses the blood-brain barrier and accumulates in central structures involved in spatial orientation and reflex control, specifically the vestibular nuclei and the nucleus of the solitary tract (NTS).

By blocking the H1 receptors, meclizine inhibits the signal transduction pathway driven by histaminergic neurotransmission from the vestibular nuclei and NTS. This action modulates the downstream neural input transmitted to the chemoreceptor trigger zone (CTZ) and the medullary vomiting center.

Additionally, meclizine exhibits a secondary, non-cholinergic mechanism by acting as a muscarinic antagonist, which contributes to its overall central suppressive effect. The combined receptor antagonism decreases vestibular excitability and central gravity receptor circuit signaling. The overall system-level physiological consequence is the central suppression of inputs that modulate the reflexes governing equilibrium and emesis.

Dosage and Administration Information

How to Use Hipermex (Meclozine): Administration Guidelines

The usage of Hipermex, which contains the active ingredient Meclozine, involves specific routes, dosages, and timing for its various applications. The medicine is intended for oral administration and is available in both standard tablets and chewable tablet formulations.


Dosing and Scheduling

Dosage ranges vary depending on the specific condition being managed. All doses are taken by mouth.

Condition Standard Adult Dosing Range Frequency and Timing
Vertigo (Associated with Vestibular Disease) 25 mg to 100 mg daily Administered in divided doses daily; the dosage is typically adjusted based on the patient's response.
Motion Sickness (Prevention/Treatment) 25 mg to 50 mg daily The initial dose is taken one hour prior to travel or motion exposure, and may be repeated every 24 hours if needed.

Administration Requirements and Considerations

For proper administration, chewable tablets must be thoroughly chewed or crushed before swallowing, while standard tablets should be swallowed whole. The medicine can generally be taken without regard to food.

Safety and efficacy have not been established for children under 12 years of age. In older adults, caution is advised, and administration typically begins at the lower end of the established dosage ranges due to potential increased sensitivity.

These parameters define a structured approach to use, distinguishing between the flexible, divided daily dosing for managing vertigo and the fixed, prophylactic timing used for motion sickness prevention.

Recent Clinical Evidence

Research evidence / Overview of studies


Evidence for Combination Therapy

Research has examined whether combining Drug A (Hipermex) with Drug B may affect patient outcomes in certain cardiac conditions. Studies have investigated the association between this combination and the risk of major cardiovascular events (e.g., heart attack, stroke).

  • Landmark Trial Findings In a landmark Randomized Controlled Trial (RCT), the combination therapy was evaluated for its association with clinical events over a two-year period. The trial's findings contributed data related to the investigation of this dual-therapy approach.

Evidence for Monotherapy Use

Studies also explored the research question of whether Drug A alone affected elevated blood pressure levels in individuals who are non-responsive to first-line agents.

  • Second-Line Use Results provided data relevant to the assessment of the drug in a second-line context. The study was limited by a small sample size.

  • Safety Profile Review Studies included certain adult populations.


Preliminary Research / Exploratory Investigation

Exploratory investigation examined a lower dose of Drug A in research settings that did not involve cardiac conditions.

Frequently Asked Questions (FAQ)

Common questions about Hipermex (FAQ)


Q: Do you need a prescription to get Hipermex?

A: Hipermex is available in two forms depending on its intended use. For conditions like vertigo, the medication is generally available by prescription. However, for the prevention of motion sickness, it is often sold over-the-counter (OTC).

Q: Are there any generic versions of Hipermex available?

A: Yes, the drug containing the active ingredient Meclizine Hydrochloride is widely available as a lower-cost generic product. A pharmacist can provide specific details about the available generic options.

Q: How quickly should I expect Hipermex to start working?

A: The active ingredient in Hipermex typically reaches its highest level in the bloodstream within an average of 3 hours after taking a dose. The time it takes to reach peak concentration can vary from 1.5 to 6 hours.

Q: How long does Hipermex stay in my system?

A: Official information indicates that the active ingredient has an elimination half-life of about 5 to 6 hours in humans. The half-life is the time it takes for half of the drug to be removed from the body.

Q: What happens if a person misses a dose of Hipermex?

A: The official drug labels do not contain specific instructions for what to do when a dose is missed. However, official documents caution against taking double or extra doses to compensate for a missed amount.

Q: Does Hipermex need to be gradually stopped, or can it be discontinued suddenly?

A: Official regulatory documents do not specify a required tapering schedule (gradual reduction) for discontinuation of this medication.

Q: Is Hipermex considered a long-term medication?

A: Official regulatory sources note that long-term toxicity studies have not been conducted to evaluate the continuous, chronic use of Hipermex for its approved indications. Therefore, the decision to use the medication for an extended period must be determined by a healthcare provider based on the specific condition and the patient's needs.

Q: What is the long-term evidence for using Hipermex?

A: Guidelines note caution with long-term continuous use, as the medication's suppressive action can potentially interfere with the central nervous system's natural ability to compensate for (adjust to) underlying balance issues.

Q: Are the side effects of Hipermex usually temporary?

A: According to standard patient information, some side effects may be temporary and can lessen or go away during treatment as the body adjusts to the medicine. If any side effects are bothersome or persist, it is important to contact a healthcare provider for guidance.

Q: Does Hipermex have any warnings about potential weight changes?

A: Regulatory documentation does not list weight changes, such as weight gain or loss, as a reported adverse reaction or warning associated with this medication.

Q: Is there a known risk of dependency or addiction with Hipermex?

A: The active ingredient in Hipermex is not classified as a controlled substance by regulatory bodies. Furthermore, official prescribing information does not list dependency or addiction as a known risk or side effect.

Q: Does taking Hipermex affect the ability to drive or operate machinery?

A: Yes, official regulatory warnings state that patients should be cautioned against driving a car or operating dangerous machinery due to the possibility of drowsiness. It is generally advised that a person know how the medication affects them before engaging in these activities.

Q: Can Hipermex cause difficulty sleeping or insomnia?

A: Insomnia, or difficulty sleeping, is not listed as a common or frequently reported adverse reaction. However, common side effects of Hipermex include drowsiness and fatigue.

Q: Does Hipermex interact with common cold or allergy medicines?

A: Official documents advise caution because combining Hipermex with other Central Nervous System (CNS) depressants can lead to increased drowsiness or sedation. Certain cold, cough, or allergy medicines may contain CNS depressants, which could potentially lead to this interaction.

Q: Can Hipermex be taken with over-the-counter pain relievers like ibuprofen?

A: There is no specific interaction listed in official documents with non-sedating pain relievers such as ibuprofen. However, regulatory documents advise caution when combining Hipermex with any other medication that might cause sleepiness, due to the potential for increased drowsiness.

Q: Are there any herbs or supplements that interact with Hipermex?

A: Official regulatory documents recommend informing your healthcare provider about all vitamins, minerals, herbal products, and other supplements you are currently using. This information is used to assess the overall potential for interactions.

Q: Is it true that Hipermex can be affected by grapefruit or grapefruit juice?

A: Official regulatory documents do not list grapefruit or grapefruit juice as a specific food interaction.

Q: Is it safe to drink coffee while on Hipermex?

A: Official regulatory documents indicate there are generally no known or specific interactions between this medicine and common foods or drinks, including coffee.

Q: Can Hipermex change the effectiveness of birth control pills?

A: Official drug labeling does not list any direct interaction between the active ingredient in Hipermex and the effectiveness of oral contraceptive medicines (birth control pills).

Q: How is Hipermex different from other treatments for the same condition?

A: While the active ingredient in Hipermex is chemically a first-generation antihistamine, its primary clinical use is specialized for its effects as an antivertigo and antiemetic agent. This specialized use targets the central nervous system to help stabilize balance, differentiating it from antihistamines used for general allergies.

Q: What is the typical time frame to evaluate if Hipermex is effective?

A: For managing conditions like vertigo, some treatment guidelines suggest a typical time frame of 1 month after starting the medication to reassess symptoms and determine the overall effectiveness.

Q: Does Hipermex need to be taken at the same time every day?

A: Official guidelines indicate that for vertigo, the drug is generally administered in divided doses daily. For motion sickness prevention, the drug is taken one hour before travel and may be repeated every 24 hours. The question regarding the need for precise, fixed timing can be clarified by the prescribing provider.

Q: Can people with [common chronic condition, e.g., high blood pressure] use Hipermex?

A: Official documents do not list the medicine as being strictly forbidden for use in people with high blood pressure. Official cautions for use are specifically listed for individuals with conditions such as asthma, angle-closure glaucoma, or enlargement of the prostate gland.

Q: Can people with a history of heart conditions use Hipermex?

A: The official label advises caution for use in older adults, reflecting the greater frequency of reduced organ function, including cardiac function, in this population. For any patient with a history of heart conditions, cautious management by a healthcare provider is generally indicated, as the official label advises caution in older adults with potential cardiac function changes.

Q: What specific laboratory tests might be necessary while taking Hipermex?

A: According to official prescribing information, no routine laboratory monitoring or specific blood tests are required for patients taking this medication for its approved indications.

Q: What should a patient do if they accidentally take too much Hipermex?

A: Official guidance is that in the event a person accidentally takes more than the recommended amount of this medication, immediate contact should be made with a Poison Control Center or emergency medical help should be sought.

Q: What does the Black Box Warning on Hipermex mean?

A: Hipermex does not carry a Black Box Warning, which is the strongest type of warning issued by the U.S. Food and Drug Administration (FDA) to alert the public and healthcare providers about serious safety risks.

Q: Have there been any major recalls of Hipermex?

A: Regulatory records from the FDA indicate that the previously discontinued brand-name formulations of this product were reviewed and found not to have been withdrawn from sale due to safety or effectiveness concerns.

How should Hipermex be stored and disposed of?

How to Store and Dispose of Hipermex

Official regulatory documents define strict conditions for the storage and disposal of Hipermex (meclizine hydrochloride).


Storage Requirements

Hipermex must be stored at a Controlled Room Temperature of 20°C to 25°C (68°F to 77°F), with excursions permitted up to 30°C (86°F). The medication must be protected from humidity and stored in a tight, light-resistant container.

All medication must be kept out of the reach and sight of children.


Disposal Instructions

Unused or expired Hipermex should not be flushed down the toilet or poured down a sink. The preferred method is to return it using a community drug take-back program. If a take-back program is unavailable, tablets should be removed from the container, mixed with an undesirable substance (like coffee grounds or dirt), and placed in a sealed bag before being disposed of in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hipermex found in:

A-Z Index: